TY  - GEN 
AU  - Torres García, Alicia
AU  - Torrente López, Anabel
AU  - Hermosilla Fernández, Jesús
AU  - Hernández, Amparo
AU  - Salmerón García, Antonio
AU  - Cabeza, José
AU  - Navas Iglesias, Natalia Africa
PY  - 2024
UR  - https://hdl.handle.net/10481/96611
AB  - Background/Objectives: Cetuximab, formulated in Erbitux® (5 mg/mL), is a therapeutic
monoclonal antibody (mAb) widely used in several cancer treatments. Currently, there is insufficient
knowledge about the behavior of cetuximab with regard to the...
LA  - eng
PB  - MDPI
KW  - cetuximab characterization
KW  - Erbitux® analysis
KW  - stability study
TI  - Comprehensive Analysis of Cetuximab Critical Quality Attributes: Impact of Handling on Antigen-Antibody Binding
DO  - 10.3390/pharmaceutics16091222
ER  -